Do IVF Treatments Have Side Effects? Reproductive Doctors Explain Real Risks and Medical Strategies

Opening: Real Consultation Scenario

"Doctor, I am 38 years old with an AMH level of 1.2. I heard that IVF can cause breast cancer and premature aging. Is that true?"
This is a question I encounter every week in the reproductive clinic. For patients considering IVF, side effects and safety are always the top concerns. Today, I will break down this issue clearly from the practical clinical perspective of reproductive medicine.

Module A: Direct Answer to the Question

1. Does IVF Actually Have Side Effects?

Direct answer: Yes, but the vast majority are controllable, reversible, and short-term. The incidence of severe complications (such as severe OHSS, intra-abdominal bleeding, infection) is low, and with the standardization of techniques and the popularization of individualized protocols, these risks are further decreasing.

The so-called "side effects" are mainly distributed in three stages: the ovulation stimulation stage, the egg retrieval surgery stage, and the embryo transfer and subsequent stages. Additionally, there is another aspect often overlooked by many — psychological burden. These are explained one by one below.

Module B: Why These Side Effects Occur

2. Where Do Side Effects Come From? — Explanation of the Medical Mechanism

The "side effects" of IVF are essentially physiological reactions caused by exogenous hormonal intervention and minimally invasive surgical procedures.

Reasons for Reactions During the Ovulation Stimulation Stage

• Injection site reactions: Gonadotropins (Gn) are administered subcutaneously. Some patients may experience local redness, swelling, induration, or mild pain, related to drug irritation or injection technique, usually resolving spontaneously within 2–3 days.
• Bloating, nausea: Simultaneous development of multiple follicles causes an increase in ovarian volume and a rapid rise in estrogen levels, stimulating gastrointestinal smooth muscle, leading to bloating, decreased appetite, or even nausea.
• Mood swings: Fluctuations in estrogen and progesterone can affect central neurotransmitters (such as serotonin), leading to anxiety, irritability, or insomnia, which are hormone-related emotional reactions.

Sources of Risk in Egg Retrieval Surgery

• Bleeding: The puncture needle passes through the vaginal fornix into the ovary, potentially damaging small blood vessels. The vast majority are puncture site oozing, which can be stopped by pressure; intra-abdominal bleeding (incidence about 0.1%) requires emergency treatment.
• Infection: Preoperative vaginal preparation, intraoperative aseptic technique, and postoperative prophylactic antibiotics have controlled the infection rate to below 0.3%.
• Anesthesia risk: In China, egg retrieval mostly uses intravenous general anesthesia or propofol sedation. Cardiopulmonary function is assessed preoperatively, and severe anesthesia-related complications are extremely rare.

Module G: The Most Easily Overlooked Details

3. The Most Easily Overlooked Details: Psychological Burden and Spousal Support

Many patients focus entirely on physical reactions but underestimate the impact of psychological stress on IVF outcomes. A clinical observation involving 1200 couples showed that patients with high anxiety scores had lower numbers of oocytes retrieved and embryo implantation rates compared to the emotionally stable group.

• Insufficient communication: Differences in perception of side effects between partners can lead to mutual blame. It is recommended to receive a joint consultation with a doctor before starting the cycle.
• Sleep disturbances: Hormonal fluctuations combined with anxiety can easily cause difficulty falling asleep or early awakening, further affecting endocrine stability.
• Dietary misconceptions: Some people over-nourish, while others fast completely due to nausea, both of which are detrimental to follicle development and endometrial preparation.

Module C: The Doctor's Perspective

4. How Do Doctors View These Risks? — Risk Assessment and Benefit Balance

As reproductive doctors, we do not assess "whether there are side effects," but rather whether the risks are within a controllable range and whether the benefits outweigh the risks.

Take OHSS (Ovarian Hyperstimulation Syndrome) as an example. The incidence of moderate to severe OHSS is about 3–6%, but after identifying high-risk groups (young age, Polycystic Ovary Syndrome, AMH > 4.5 ng/mL, history of OHSS), the risk can be significantly reduced through the following measures:

• Using GnRH agonist trigger instead of HCG trigger
• Reducing HCG dosage or delaying trigger timing
• Elective embryo freezing strategy to avoid exacerbation of the condition by endogenous HCG from pregnancy

Regarding long-term safety, a cohort study published in the British Medical Journal in 2021 covering 250,000 women showed no significant difference in the incidence of breast cancer, ovarian cancer, or endometrial cancer between women who received ovulation stimulation treatment and those who conceived naturally. Large-sample data from Peking Union Medical College Hospital and the Reproductive Hospital Affiliated to Shandong University in China also support this conclusion.

Module H: Common Pitfalls

5. Common Pitfalls: Misinterpretation of Information and Excessive Anxiety

In clinical practice, we often encounter patients who are overly nervous because of "what they read online." The following issues are the most common:

Myth 1: Ovulation stimulation depletes eggs, causing premature ovarian failure

Truth: Each menstrual cycle, a cohort of follicles enters the growth trajectory. Only one dominant follicle ovulates, while the rest regress through apoptosis. Ovulation stimulation drugs merely "rescue" a batch of follicles that were destined to regress, rather than prematurely consuming the future follicle reserve. Therefore, ovulation stimulation does not cause premature ovarian failure, but it may accelerate the depletion of an already limited follicle reserve — this is not due to drug toxicity but a physiological mechanism.

Myth 2: Bloating after egg retrieval is normal and should be endured

Truth: Mild bloating and a small amount of bloody vaginal discharge after egg retrieval are normal. However, if you experience progressively worsening bloating, decreased urine output (less than 800 mL per day), difficulty breathing, or rapid weight gain, these could be early signs of OHSS and require prompt return to the hospital for examination.

Myth 3: Strict bed rest is required after transfer; no activity is allowed

Truth: Prolonged bed rest is not only detrimental to blood circulation but also increases the risk of thrombosis. Living normally and taking moderate walks after transfer actually helps uterine blood perfusion. The only things to avoid are strenuous exercise, lifting heavy objects, and prolonged standing.

Module D: Differences Across Age Groups

6. Risk Differences Among Patients of Different Ages

Age is one of the most critical variables affecting IVF risk and treatment strategy. The table below summarizes common differences across age groups:

Age Group	Main Risk Characteristics	Doctor's Focus
≤ 35 years	Good ovarian response, relatively higher OHSS risk; good egg quality, higher success rate per cycle	Control ovulation stimulation dosage, prevent OHSS; avoid multiple pregnancies
36–40 years	Ovarian reserve begins to decline, fewer oocytes retrieved after stimulation; increased aneuploidy rate in eggs	Individualized ovulation stimulation protocol; consider PGT-A (Preimplantation Genetic Testing for Aneuploidy) if necessary
≥ 41 years	Further decrease in oocyte number, increased cycle cancellation rate; higher miscarriage rate after pregnancy	Thoroughly assess ovarian reserve; counseling on egg donation; focus on managing cardiovascular and metabolic risks

Older patients generally tolerate ovulation stimulation drugs well and have a lower risk of OHSS, but more attention needs to be paid to the impact of underlying diseases (such as hypertension, diabetes) on pregnancy.

Module M: Case Scenario Analysis

7. Real Case: Risk Identification and Management

Case: A 31-year-old female patient with a history of Polycystic Ovary Syndrome (PCOS), AMH 6.8 ng/mL, BMI 22. After the first ovulation stimulation, 22 oocytes were retrieved. On the 3rd day after the trigger, she experienced worsening bloating, nausea and vomiting, and decreased urine output to 600 mL/day. Ultrasound showed an ovarian diameter of 10 cm and ascites depth of 5.2 cm. Diagnosis: Moderate OHSS.

Management Process:

• Embryo transfer was suspended, the fresh cycle was cancelled, and all embryos were frozen.
• Outpatient fluid resuscitation: Intravenous infusion of albumin plus crystalloids to correct electrolyte imbalance.
• Monitoring of urine output, body weight, abdominal circumference, and liver/kidney function.
• Symptoms gradually resolved after 7 days; ovarian size decreased to 6 cm, and ascites was absorbed.

Outcome: A frozen embryo transfer (single blastocyst) was performed 2 months later, resulting in a successful pregnancy and delivery. This case illustrates that even if OHSS occurs, standardized management generally leaves no sequelae and does not affect the success rate of subsequent transfers.

Module R: Practitioner Observations

8. Practitioner Observations: The Three Most Underestimated Things

In my years working in a reproductive center, I believe three aspects need more attention:

• Spousal involvement: Many women bear most of the treatment stress alone, but male factors (such as semen quality, psychological support) are equally critical to the outcome. It is recommended that the male partner participate in at least the initial consultation and the process on the day of sperm collection.
• Pre-cycle metabolic conditioning: Subclinical issues such as insulin resistance, vitamin D deficiency, and thyroid dysfunction, if not corrected before starting the cycle, can reduce egg quality and endometrial receptivity. It is recommended to complete relevant examinations and interventions 2–3 months in advance.
• Luteal phase support after transfer: The choice of progesterone preparation (oral, vaginal gel, or injection) should be based on the patient's constitution and preference. For patients who have poor absorption or allergies to injections, switching to a vaginal preparation can be considered, as its endometrial transformation effect is not inferior to injections.

Ending: Risk Reminder (Randomly Selected)

---